Company Profile

Company Overview

Lindy Biosciences has developed a formulation platform that enables highly concentrated suspensions of proteins, allowing higher dosing in smaller volumes, ultimately allowing patients to self-administer biologics at home. Despite the industry pushing for more patient-centric care, many biologics must still be given in a clinical setting through lengthy IV infusions which are costly, inconvenient, and invasive. Ideally, these drugs would be given by a single subcutaneous injection that patients could administer themselves.

Lindy’s suspensions of highly concentrated proteins address these challenges, ultimately reducing the time patients spend taking medication. Lindy’s proprietary Microglassification technology and suspension platform improves stability and reduces viscosity enabling concentrations of 400 mg/mL and higher. Microglassification is a dehydration technology that results in stable, dense, spherical particles of amorphous, solid protein. By combining the stability of a solid formulation with the convenience of a ready-to-inject formulation, Lindy’s suspension platform can vastly improve the administration of therapeutic biologics. This improves patient compliance, decreases costs, and enables new high-dose molecules to reach the market. Patients have the option to self-administer their medication via pre-filled syringe and/or autoinjector (within seconds) in the privacy of their home rather than spending hours in a clinic. This is a dramatic quality of life improvement.

Lindy is currently collaborating with multiple pharmaceutical companies to help advance their biotherapeutic programs from pipeline to patients.